Last updated: February 15, 2026
Overview:
NDC 70165-0005 refers to Gilead Sciences’ remdesivir (brand name: Veklury). Approved by the FDA in October 2020 for COVID-19 treatment, remdesivir is an antiviral drug used primarily in hospitalized patients.
Market Size and Trends:
The global COVID-19 therapeutics market faced an initial surge with the pandemic, peaking around 2021–2022. As of 2023, demand shifts toward outpatient treatments and combination therapies, but remdesivir remains a key hospital-administered antiviral for severe cases.
- Market valuation (2023 estimate): Approximately $2.5 billion globally, with North America accounting for 70%, Europe 20%, Asia-Pacific 8%, others 2%.
- Key consumers: Hospitals, government agencies, health systems.
- Sales drivers: COVID-19 case rates, health policy changes, pricing agreements, and insurance reimbursement policies.
Competitive Landscape:
Remdesivir's main competitors include alternative antiviral agents, such as molnupiravir (Merck), paxlovid (Pfizer), and emerging oral therapeutics. Yet, remdesivir retains unique positioning as the only IV antiviral authorized by the FDA for hospitalized patients.
- Market share (2023): Remdesivir controls roughly 65% of the COVID-19 antiviral market within hospitals.
- Pricing comparison:
- Gilead's remdesivir: $520 per vial (initial average list price).
- Molnupiravir: $700 for a five-day course (oral).
- Paxlovid: $530 for five days (oral).
Pricing Dynamics and Projections:
Price variations stem from manufacturer negotiations, licensing deals, and government procurement agreements. Gilead initially set the list price at approximately $520 per vial, with a typical course consisting of six vials, totaling about $3,120 per treatment.
Regulatory and Policy Influence:
Remdesivir retains FDA approval expiration currently unknown, with Gilead actively defending patent protections. Any patent lapses or loosening of restrictions could introduce generics, potentially reducing prices to levels comparable with small-molecule antivirals available outside the US.
Market Entry and Expansion Opportunities:
- Emerging markets: Gilead is expanding access via licensing agreements; expect lower prices aligned with regional income levels.
- New indications: Research on remdesivir for other viral infections (e.g., Ebola, hepatitis) could expand markets, but current evidence does not support significant sales growth outside COVID-19.
Summary Table:
| Aspect |
2023 Data |
2028 Projection |
| Market size |
~$2.5 billion |
Slight decline to ~$2.0 billion |
| Market share |
65% in hospital settings |
Stable or slight decrease |
| Average price per vial |
~$520 (list), ~$390–$440 (negotiated) |
$470–$500 with potential discounts |
| Demand |
High in severe cases, stable |
Slight decrease as oral agents gain popularity |
Key Takeaways
- The remdesivir market remains sizable but faces long-term pressure from competitive oral antivirals.
- Price points are likely to decrease marginally due to negotiations and increased supply, possibly by 5–10% over five years.
- The market is geographically concentrated in high-income countries, with expanding access in emerging markets through licensing.
- The eventual patent expiry or regulatory changes could lead to significant price reductions if generics enter the market.
- Ongoing clinical trials and new indications may influence future demand and pricing dynamics.
FAQs
1. What factors influence remdesivir's future pricing?
Patents, competition from oral antivirals, government procurement policies, and manufacturing costs impact pricing. Patents protect exclusivity until around 2030, after which generics could emerge.
2. How does remdesivir compare in cost to its competitors?
List prices are similar: remdesivir around $520 per vial, paxlovid at $530 for five days, molnupiravir $700 for five days. However, oral agents may be more cost-effective per course.
3. Is remdesivir likely to expand into new therapeutic areas?
Current studies are ongoing, but no significant expansion is anticipated unless new indications are supported by data, which could broaden demand.
4. How do government contracts affect remdesivir’s market price?
US government procurement agreements have historically negotiated prices below list prices, reducing costs for hospitals and insurers.
5. What is the outlook if generics enter the market?
Prices could fall by 80% or more, similar to other antiviral drugs, drastically reducing revenue for Gilead and shifting market dynamics.
References
- Gilead Sciences. Veklury (remdesivir) Pricing and Supply, 2023.
- IQVIA. COVID-19 Therapeutics Market Report, 2023.
- FDA. Remdesivir (Veklury) Labeling Information, 2022.
- MarketWatch. Antiviral Drugs Market Size and Forecast, 2023.
- Evenstad, J. "Generic Entry and Price Erosion in Antiviral Market," Journal of Pharmaceutical Economics, 2022.
